

# 16 Poliomyelitis

## Key information

Mode of transmission	Faecal–oral route or by ingestion of pharyngeal secretions.
Incubation period	Paralytic disease usually 7–14 days, with a reported range of 3–35 days.
Period of communicability	Most infectious in the days immediately before and after the onset of any symptoms. Transmission is possible as long as the virus is shed (can be years in immunocompromised individuals).
Global burden of disease	Endemic in Afghanistan, Nigeria and Pakistan. Outbreaks are still frequent.
Funded vaccines	As inactivated polio vaccine (IPV), in combination with other antigens, or on its own: <ul style="list-style-type: none"> <li>• DTaP-IPV-HepB/Hib (Infanrix-hexa)</li> <li>• DTaP-IPV (Infanrix-IPV)</li> <li>• IPV (IPOL).</li> </ul>
Dose, presentation, route	All 0.5 mL per dose. DTaP-IPV-HepB/Hib: pre-filled syringe and glass vial, the vaccine must be reconstituted prior to intramuscular injection. DTaP-IPV: pre-filled syringe, intramuscular injection IPV: pre-filled syringe, subcutaneous injection
Funded vaccine indications and schedule	Usual childhood schedule: <ul style="list-style-type: none"> <li>• at age 6 weeks, 3 months and 5 months: DTaP-IPV-HepB/Hib (primary series)</li> <li>• at age 4 years: DTaP-IPV (booster).</li> </ul> For non-immune adults, 3 doses of IPV 8 weeks apart (may be shortened to 4-week intervals). For (re-)vaccination of eligible patients: DTaP-IPV-HepB/Hib, DTaP-IPV or IPV.
Vaccine efficacy/effectiveness	Greater than 90 percent.
Precautions	Non-immune pregnant women may be immunised if they are travelling to a region where polio is endemic.

## 16.1 Virology

Poliomyelitis (polio) is a highly transmissible infectious disease caused by poliovirus, a small, non-enveloped enterovirus of the family Picornaviridae. There are three serotypes of poliovirus (types 1, 2 and 3), with type 2 now eliminated.

## 16.2 Clinical features

Poliovirus is transmitted by the faecal–oral route or by ingestion of pharyngeal secretions. The incubation period for poliomyelitis is commonly 7 to 14 days for paralytic disease, with a reported range of 3 to 35 days. The risk of transmission of infection is greatest shortly before to shortly after the onset of symptoms. The virus persists in the pharynx for approximately one week, and in the faeces for three to six weeks or longer, particularly in immunocompromised individuals, where cases have been reported shedding for many years.

The virus is highly neurotropic and its primary effect occurs in the neurones of the spinal anterior horn or the motor ganglia of the brain stem. Infection is clinically inapparent in up to 95 percent of infections, and ranges in severity from a non-paralytic fever to viral meningitis and flaccid paralysis.

Symptoms include fever, headache, gastrointestinal disturbances, malaise, stiffness of the neck and back, and pain in the limbs, back and neck, with or without paralysis. In children who develop paralysis, the illness may be biphasic, the initial phase of one to three days' duration being indistinguishable from that of other viral infections. The patient appears to recover, only to be struck down abruptly two to five days later with meningism, followed by paralysis. In adults and adolescents the illness usually presents with a gradual onset of paralysis and pain without the early symptoms.

Asymptomatic people with the infection will shed the virus in their stool and may spread the infection to others. Infection rates may be as high as 100 percent in households where there are non-immune young children, although paralysis may occur in only 0.1–2 percent of infected individuals. Paralysis is more common in adults, occurring in up to 1 in 75 cases of infection.

Case fatalities from paralytic polio vary from 2–5 percent among children and up to 15–30 percent for adults, increasing to 25–75 percent with bulbar involvement.

The post-polio syndrome may occur some 30 to 40 years after poliomyelitis. The cause is not known, but is probably related to the ageing or death of nerves and muscles that were compensating for the original damage. Patients experience muscle pain and exacerbation of existing muscle weakness. The risk of developing post-polio syndrome is greater in women than in men, and the risk increases with time from the episode of acute polio.

## **16.3 Epidemiology**

### **16.3.1 Global burden of disease**

In the pre-vaccination era, cases of poliomyelitis occurred sporadically and in epidemics in high-income countries in temperate zones. In tropical countries, where the virus still circulates, there is no seasonal pattern.

Classically, poliomyelitis is a disease of young children and adolescents. However, with improvements in living standards, a greater number of cases have occurred in older individuals, with an associated higher frequency of paralytic disease. Paralytic disease is a particular risk in early adult life. In countries where polio was endemic, most children acquired antibodies to all three subtypes by age 5 years and most paralytic disease occurred in children aged under 3 years.

The resurgence of polio in some countries occurred because of the introduction of wild-type polio virus into poorly immunised populations.

Polio remains endemic in Afghanistan, Nigeria and Pakistan, and other countries are vulnerable to international spread. For up-to-date surveillance information, see the ‘Polio Now’ section of the Global Polio Eradication Initiative website ([polioeradication.org/polio-today/polio-now](http://polioeradication.org/polio-today/polio-now)).

The Polio Eradication & Endgame Strategic Plan 2013–2018<sup>1</sup> was developed by the Global Polio Eradication Initiative. Its goal is ‘the complete eradication and containment of all wild, vaccine-related and Sabin polioviruses’ by 2018. The Americas were certified polio-free in 1994. The Western Pacific, which includes New Zealand, was the second region to be certified polio-free, in October 2000, with no indigenous polio cases reported since March 1997. Vaccination against polio will continue worldwide until the disease has been eradicated.

### **Vaccine-associated paralytic poliomyelitis (VAPP) with oral polio vaccine (OPV)**

After receiving OPV, most infants excrete the polio vaccine virus for about six weeks. Close contacts may acquire then excrete the virus in faeces. There is a small risk that the vaccine virus may revert to neurovirulence and cause VAPP in a vaccine recipient or non-immune contact. VAPP presents with acute flaccid paralysis (AFP) 7 to 30 days after vaccination in the recipient, and from 7 to 60 days in the contact of a vaccine recipient. The immunocompromised are at greater risk of VAPP, either as vaccine recipients or contacts. In New Zealand VAPP can only occur from contact with people vaccinated in countries still using OPV.

Once wild virus became uncommon, the risk of VAPP became higher than the risk of imported wild virus disease. This led New Zealand to change from OPV to IPV in 2002 to eliminate the risk of VAPP (see Appendix 1). The last case of VAPP in New Zealand occurred in 1999.<sup>2</sup>

#### **16.3.2 New Zealand epidemiology**

Since 1962 only six polio cases have been reported. Four of these cases were laboratory confirmed as VAPP and two were classified as probable VAPP.

The New Zealand Paediatric Surveillance Unit carries out active surveillance of AFP. In 2015 there were seven notifications: all were reviewed by the New Zealand National Certification Committee for the Eradication of Polio and all were classified as non-polio.<sup>3</sup>

The risk of importing wild-type or neurovirulent oral vaccine-derived strains means that maintaining high IPV coverage in New Zealand is essential.

## 16.4 Vaccines

New Zealand switched from OPV to IPV in 2002 (see Appendix 1).

### 16.4.1 Available vaccines

#### Funded polio vaccines

The polio-containing vaccines funded as part of the Schedule are:

- DTaP-IPV-HepB/Hib (Infanrix-hexa, GSK): diphtheria, tetanus, acellular pertussis, inactivated polio, hepatitis B and *Haemophilus influenzae* type b vaccine (see section 5.4.1 for more information)
- DTaP-IPV (Infanrix-IPV, GSK): diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (see section 5.4.1 for more information)
- IPV (IPOL, Sanofi): contains three strains of poliovirus (40D antigen units of the Mahoney, 8D antigen units of the MEF-1, and 32D antigen units of the Saukett strains), inactivated by formaldehyde and containing phenoxyethanol as a preservative; trace amounts of neomycin, streptomycin, polymyxin B, polysorbate 80 and bovine serum albumin may be present.

#### Other vaccine

Another polio-containing vaccine registered (approved for use) and available (marketed) in New Zealand is:

- Tdap-IPV: Adacel Polio (Sanofi).

### 16.4.2 Efficacy and effectiveness

See also section 14.4.2 for information about DTaP-IPV-HepB/Hib vaccine.

## **Immunogenicity and efficacy**

Virtually all infants (99–100 percent) will seroconvert against all three strains after three doses of IPV vaccine, and more than 95 percent will seroconvert after two doses.<sup>4</sup> The efficacy of IPV is greater than 90 percent<sup>5</sup> and immunity is expected to be long lasting.<sup>4</sup> Although antibody may decline over time in some individuals, there is no evidence that this leads to increased susceptibility to poliomyelitis.<sup>6</sup>

The combined IPV-containing vaccines induce immune responses against polioviruses superior to IPV stand-alone vaccines. This is due to the effect of the aluminium adjuvant present in these combination vaccines.<sup>5</sup>

### **16.4.3 Transport, storage and handling**

Transport according to the *National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017*.<sup>7</sup> Store at +2°C to +8°C. Do not freeze.

DTaP-IPV-HepB/Hib vaccine should be stored in the dark.

DTaP-IPV-HepB/Hib (Infanrix-hexa) must be reconstituted by adding the entire contents of the supplied container of the DTaP-IPV-HepB vaccine to the vial containing the Hib pellet. After adding the vaccine to the pellet, the mixture should be shaken until the pellet is completely dissolved. Use the reconstituted vaccine as soon as possible. If storage is necessary, the reconstituted vaccine may be kept for up to eight hours at 21°C.

### **16.4.4 Dosage and administration**

The dose of DTaP-IPV-HepB/Hib (Infanrix-hexa) and DTaP-IPV (Infanrix-IPV) is 0.5 mL, administered by intramuscular injection (see section 2.2.3).

The dose of IPV (IPOL) is 0.5 mL, administered by subcutaneous injection (see section 2.2.3).

## Co-administration with other vaccines

DTaP-IPV-HepB/Hib, DTaP-IPV and IPV may be given at the same time as inactivated or live attenuated vaccines, at separate sites and in separate syringes.

## 16.5 Recommended immunisation schedule

**Table 16.1: Immunisation schedule for IPV-containing vaccines (excluding catch-up)**

Age	Vaccine	Comment
6 weeks	DTaP-IPV-HepB/Hib	Primary series
3 months	DTaP-IPV-HepB/Hib	Primary series
5 months	DTaP-IPV-HepB/Hib	Primary series
4 years	DTaP-IPV	Booster

### 16.5.1 Usual childhood schedule

A primary course of poliomyelitis vaccine is given as DTaP-IPV-HepB/Hib at ages 6 weeks, 3 months and 5 months, followed by a booster dose given as DTaP-IPV at age 4 years.

### 16.5.2 Unimmunised adults and children

For partially immunised or previously unimmunised individuals, a primary immunisation course consists of three doses of IPV-containing vaccine (funded). The recommended interval is eight weeks between doses, but the minimum interval can be as short as four weeks for catch-up of children or adults<sup>8</sup> (see Appendix 2).

If a course of vaccine is interrupted, it may be resumed without repeating prior doses. A booster may be given if 10 years have elapsed since the last dose and exposure is possible (eg, in the case of a traveller to an area where the virus circulates; this is not funded).

If a child who began a course of OPV in another country moves to New Zealand, they can switch to IPV to complete the final doses.

Note: All immunocompromised individuals and their household contacts may receive IPV. OPV was contraindicated in the immunocompromised because of the risk of VAPP (see section 16.3.1). There is no risk of VAPP with IPV.

### **16.5.3 Pregnancy and breastfeeding**

No adverse effects on the fetus have been reported following administration of IPV during pregnancy, but immunisation should not be carried out during the first or second trimester unless there are compelling reasons to do so, such as planned travel to an endemic area. However, bear in mind that pregnant women are particularly susceptible to paralytic polio.

If a previously unvaccinated pregnant woman is travelling to a country where polio is occurring, two doses should be administered four weeks apart prior to departure. If departure cannot be delayed to allow a four-week gap, give two doses at the maximum possible interval, though protection cannot be guaranteed. If the available interval is less than two weeks, a single dose is recommended, with further doses given on arrival where possible.

IPV may be given to breastfeeding women.

### **16.5.4 (Re-)vaccination**

Polio-containing vaccines are funded for (re-)vaccination of eligible patients, as follows. See also sections 4.2 and 4.3.

#### **DTaP-IPV-HepB/Hib (Infanrix-hexa) and DTaP-IPV (Infanrix-IPV)**

An additional four doses (as appropriate) of DTaP-IPV-HepB/Hib (for children aged under 10 years) or DTaP-IPV are funded for (re-)vaccination of patients:

- post-HSCT or chemotherapy
- pre- or post-splenectomy
- pre- or post-solid organ transplant

- undergoing renal dialysis
- with other severely immunosuppressive regimens.

Up to five doses of DTaP-IPV-HepB/Hib (for children aged under 10 years) or DTaP-IPV are funded for children requiring solid organ transplantation.

## **IPV (IPOL)**

IPV is funded for patients following immunosuppression.

### **16.5.5 Recommendations for other groups**

Booster doses of IPV are recommended (but not funded) for:

- travellers to areas or countries where poliomyelitis remains endemic (see section 16.3.1); a booster of IPV is recommended for these individuals if more than 10 years have elapsed since their last dose (where there is uncertainty about previous immunisation, a full course of IPV is recommended)
- health care workers in direct contact with a case of poliomyelitis
- individuals at particular risk of exposure (eg, laboratory workers routinely handling faecal specimens from persons recently arriving from high-risk countries, which may contain wild or vaccine-derived polioviruses); a booster dose of IPV is recommended every 10 years.

There is no evidence for the need for routine boosters, but they are recommended to reduce any possible risk from waning immunity in situations of increased risk of exposure.

## **16.6 Contraindications and precautions**

See also section 2.1.3 for pre-vaccination screening guidelines and section 2.1.4 for general contraindications for all vaccines.

### **16.6.1 Contraindications**

IPV-containing vaccines are contraindicated if there is a history of an anaphylactic reaction to a previous dose or to any of the vaccine components.

See also section 14.6 for information about DTaP-IPV-HepB/Hib vaccine.

### **16.6.2 Precautions**

Pregnancy is a precaution for IPV-containing vaccines. See section 16.5.3.

## **16.7 Expected responses and AEFIs**

See also section 14.7 for information about DTaP-IPV-HepB/Hib and DTaP-IPV vaccines.

### **16.7.1 Expected responses**

A small proportion of individuals experience mild local symptoms following IPV. Injection site erythema is seen in 1–2 percent of infants, induration in 3–11 percent and pain in 14–29 percent. Similar local reactions are seen with combination vaccines.<sup>5</sup> There is no poliovirus excretion following IPV.

### **16.7.2 AEFIs**

In safety studies of IPV with combined vaccines, symptoms of irritability (14–37 percent), sleepiness (2–23 percent), diarrhoea (2–9 percent), vomiting (1–8 percent) and fever over 39°C (1–3 percent) have been reported after primary immunisation of infants (see the manufacturer's data sheet for IPOL).

Serious adverse events are very rare following administration of the IPV currently manufactured.<sup>4</sup>

## **16.8 Public health measures**

It is a legal requirement that all suspected cases of poliomyelitis be notified immediately on suspicion to the local medical officer of health.

Collect two faecal specimens 24 hours apart, 0 to 14 days after the onset of paralysis and send to the national poliovirus reference laboratory at ESR.

Contact the polio reference laboratory for specific advice on the specimens required, and on packing and transporting the specimens (see also the 'Single human source specimen form', available on the ESR website: [www.esr.cri.nz/health-science/test-request-forms/](http://www.esr.cri.nz/health-science/test-request-forms/)).

Cases of AFP must be investigated as suspected poliomyelitis. All clinicians caring for any person aged under 15 years with AFP must notify the case to the local medical officer of health and report the case to the New Zealand Paediatric Surveillance Unit. If in a hospital, all cases of AFP should also be discussed with a local microbiologist and infection control service.

Case investigation and surveillance for AFP will continue in New Zealand to monitor the successful eradication of polio.<sup>9</sup> The New Zealand Paediatric Surveillance Unit is based at the University of Otago and is responsible for sending case investigation and follow-up forms to clinicians to continue to monitor that New Zealand has eradicated polio and to provide information to the WHO.

Any case of poliomyelitis in New Zealand constitutes a Public Health Emergency of International Concern, and the Director of Public Health at the Ministry of Health should be contacted urgently. The *National Poliomyelitis Response Plan for New Zealand*<sup>9</sup> outlines the actual response and is published on the Ministry of Health website ([www.health.govt.nz](http://www.health.govt.nz)).

Although polio has been eradicated in the WHO Western Pacific Region, New Zealand will need to continue with high levels of IPV coverage. This is because of the small risk that polio may be imported from another region where polio remains endemic (see section 16.3.1).

For more details on control measures, refer to the 'Poliomyelitis' chapter of the *Communicable Disease Control Manual 2012*.<sup>10</sup>

## 16.9 Variations from the vaccine data sheets

See section 14.9 for variations from the DTaP-IPV-HepB/Hib (Infanrix-hexa) and DTaP-IPV (Infanrix-IPV) data sheets.

The IPV (IPOL) data sheet recommends three doses of vaccine administered at eight-week intervals. The Ministry of Health recommends that this schedule may be shortened to four-week intervals for catch-up<sup>8</sup> (see Appendix 2).

### References

1. Global Polio Eradication Initiative. 2013. *Polio Eradication & Endgame Strategic Plan 2013–2018*. URL: [www.polioeradication.org/resourcelibrary/strategyandwork.aspx](http://www.polioeradication.org/resourcelibrary/strategyandwork.aspx) (accessed 17 September 2013).
2. Edwards EA, Grant CC, Huang QS, et al. 2000. A case of vaccine-associated paralytic poliomyelitis. *Journal of Paediatrics & Child Health* 36(4): 408–11.
3. Institute of Environmental Science and Research Ltd. 2016. *Notifiable Diseases in New Zealand: Annual Report 2015*. URL: [https://surv.esr.cri.nz/PDF\\_surveillance/AnnualRpt/AnnualSurv/2015/2015AnnualReportFinal.pdf](https://surv.esr.cri.nz/PDF_surveillance/AnnualRpt/AnnualSurv/2015/2015AnnualReportFinal.pdf) (accessed 16 November 2016).
4. American Academy of Pediatrics. 2015. Poliovirus infections. In: Kimberlin DW, Brady MT, Jackson MA, et al (eds). *Red Book: 2015 Report of the Committee on Infectious Diseases* (30th edition). Elk Grove Village, IL: American Academy of Pediatrics.
5. Vidor E, Plotkin SA. 2013. Poliovirus vaccine – inactivated. In: Plotkin SA, Orenstein WA, Offit PA (eds). *Vaccines* (6th edition). Philadelphia, PA: Elsevier Saunders.
6. World Health Organization. 2016. Polio vaccines: WHO position paper, March 2016. *Weekly Epidemiological Record* 91(12): 145–68. URL: <http://www.who.int/wer/2016/wer9112.pdf?ua=1> (accessed 29 March 2017).
7. Ministry of Health. 2017. *National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017*. URL: [www.health.govt.nz/coldchain](http://www.health.govt.nz/coldchain) (accessed 14 February 2017).

8. Department of Health and Ageing. 2016. Poliomyelitis. In: *The Australian Immunisation Handbook* (10th edition; updated August 2016). URL: <http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-14> (accessed 30 November 2016).
9. Ministry of Health. 2014. *National Poliomyelitis Response Plan for New Zealand*. URL: [www.health.govt.nz/publication/national-poliomyelitis-response-plan-new-zealand](http://www.health.govt.nz/publication/national-poliomyelitis-response-plan-new-zealand) (accessed 30 June 2015).
10. Ministry of Health. 2012. *Communicable Disease Control Manual 2012*. URL: <http://www.health.govt.nz/publication/communicable-disease-control-manual-2012> (accessed 15 November 2016).